Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Compugen Ltd. (NASDAQ:CGEN) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $5.00.

A number of brokerages have weighed in on CGEN. Truist Financial raised Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Lake Street Capital started coverage on Compugen in a research note on Tuesday, April 7th. They set a “buy” rating and a $6.00 target price for the company. Leerink Partners lowered their target price on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Wall Street Zen upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th.

Institutional Investors Weigh In On Compugen

Several hedge funds have recently added to or reduced their stakes in CGEN. Renaissance Technologies LLC increased its holdings in Compugen by 12.1% in the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after purchasing an additional 176,088 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in shares of Compugen during the first quarter worth $68,000. Calamos Advisors LLC acquired a new stake in shares of Compugen during the first quarter worth $63,000. Platform Technology Partners increased its position in shares of Compugen by 10.0% during the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock worth $117,000 after buying an additional 5,000 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Compugen during the fourth quarter worth $104,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Stock Down 3.5%

Shares of NASDAQ:CGEN traded down $0.10 during midday trading on Thursday, hitting $2.61. The stock had a trading volume of 229,237 shares, compared to its average volume of 442,003. The company’s 50-day moving average price is $2.53 and its 200-day moving average price is $2.01. The company has a market capitalization of $246.31 million, a P/E ratio of 7.04 and a beta of 2.79. Compugen has a fifty-two week low of $1.29 and a fifty-two week high of $3.23.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $2.18 million during the quarter, compared to analyst estimates of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. Research analysts expect that Compugen will post -0.28 EPS for the current fiscal year.

Trending Headlines about Compugen

Here are the key news stories impacting Compugen this week:

• Positive Sentiment: Recent coverage highlighted that Compugen’s revenue beat expectations, which helped support the stock after its quarterly report despite a small EPS miss. Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN)
• Neutral Sentiment: HC Wainwright also laid out longer-term earnings estimates for FY2028 through FY2030, signaling continued coverage and a still-developing long-range view on Compugen’s profitability.
• Negative Sentiment: HC Wainwright cut its Q2, Q3, and Q4 2026 EPS estimates for Compugen to a loss of $0.10 per share, down from $0.09, indicating a slightly weaker near-term earnings outlook.
• Negative Sentiment: The firm also lowered its FY2026 EPS estimate to a $0.38 loss from a $0.36 loss, and its FY2027 estimate implies continued losses, which may weigh on sentiment for Compugen Ltd. (NASDAQ: CGEN).

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.